Skip to main content Accessibility help
×
Home
Hostname: page-component-8bbf57454-5qtdt Total loading time: 0.248 Render date: 2022-01-23T07:25:07.857Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432

Published online by Cambridge University Press:  29 June 2007

Satoshi Kitahara
Affiliation:
Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama.
Makoto Ikeda*
Affiliation:
Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama.
Tetsuzo Inouye
Affiliation:
Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama.
Takeshi Matsunaga
Affiliation:
Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama.
Kengo Yamaguchi
Affiliation:
Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama.
Etsuyo Takayama
Affiliation:
Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama.
Gerald B. Healy
Affiliation:
Department of Otology and Laryngology, Harvard Medical School, Boston, MA, USA
Mamoru Tsukuda
Affiliation:
Department of Otolaryngology, School of Medicine, Yokohama-city University, Yokohama, Japan.
*
Address for correspondence: Dr Makoto Ikeda, M.D., Ph.D., Undersea Medical Centre, 2-7-1 Nagase, Yokosuka-city, Japan. Fax: Japan (81)-429955330
Get access

Abstract

The multi-cytokine inducer OK-432 is a pulverized preparation of the low-virulence SU strain of Streptococcus pyogenes of human origin. A reduction of the tumour mass in the OK-432-injected areas was observed in 11 out of 13 patients with metastatic and/or recurrent head and neck cancer. Complete response (CR), partial response (PR) and minor response (MR) were noted in six, three and two cases respectively. OK-432 local administration therapy could create a new strategy for cancer therapy.

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Fujimori, M., Sugenoya, A., Kobayashi, S., Masuda, H., Komatsu, M., Takahashi, S., Shimizu, T., Tsuchiya, S., Iida, F. (1989) Local immunotherapy for breast cancer: case with advanced breast cancer improved by combined local injection therapy with OK-432 and rIL-2. Japanese Journal of Cancer Chemotherapy 16: 27602763.Google ScholarPubMed
Fujioka, T., Ishikura, K., Tanji, S., Okamoto, T., Koike, H., Aoki, H., Ohhori, T., Kubo, T. (1990) Combined effects of intraperitoneal administration of recombinant interleukin-2 and Streptococcal preparation OK-432 in murine tumours. International Journal of Immunopharmacology 12: 419426.CrossRefGoogle Scholar
Hirakawa, H., Akimoto, M., Matano, S., Abe, M., Mori, S. (1989) A case with multiple liver metastasis from breast cancer successfully treated by local injection of OK-432 (400KE) and trans-arterial infusion of rIL-2. Biotherapy 3: 742745.Google Scholar
Ichimura, O., Suzuki, S., Saito, M. (1985). Augmentation of interleukin 1 and interleukin 2 production by OK-432. International Journal of Immunopharmacology 7: 263268.CrossRefGoogle ScholarPubMed
Ikeda, M., Tsuru, S., Shinomiya, N., Taniguchi, M., Fujisawa, T., Zinnaka, Y. (1985) Activation of peritoneal macrophages induced by OK-432. Journal of National Defense Medical College 10: 115119.Google Scholar
Ishii, Y., Yamaoka, H., To, K., Kikuchi, K. (1976) Inhibition of tumour growth in vivo by macrophages from rat treated with a Streptococcal preparation, OK-432. Gann 67: 115119.Google ScholarPubMed
Kitahara, S., Ikeda, M., Tanabe, T., Sakata, J., Inouye, T. (1989) Treatment of head and neck cancer by OK-432 local injection. Therapeutic Research 10: 383391.Google Scholar
Kokunai, I., Mori, T., Yayoi, E., Matsuura, N., Kamimae, G. (1985) Correlation between anti-tumour effect and delayed hypersensitivity induced by topically applied OK-432 with histological findings. Japanese Journal of Surgery 86: 258265.Google Scholar
Misaki, T., Watanabe, Y., Iida, Y., Hidaka, A., Kasagi, K., Fukushima, H., Konishi, J. (1992) Recruitment of T lymphocytes and induction of tumour necrosis factor in thyroid cancer by a local immunotherapy. Cancer Immunology Immunotherapy 35: 9296.CrossRefGoogle ScholarPubMed
Mizutani, Y., Nio, Y., Yoshida, O. (1991) The Streptococcal preparation OK-432 specificity augments the susceptibility of human urinary bladder tumour cells to autologous peripheral blood lymphocytes. Cancer 69: 29993007.3.0.CO;2-A>CrossRefGoogle Scholar
Ogita, S., Tsuto, T., Deguchi, E., Tokiwa, K., Nagashima, M., Iwai, N. (1991) OK-432 therapy for unresectable lymphangiomas in children. Journal of Pediatric Surgery 26: 263270.CrossRefGoogle ScholarPubMed
Oshimi, K., Kano, S., Takaku, F., Okaumura, K. (1980a) Augmentation of mouse natural killer cell activity by a Streptococcal preparation, OK-432. Journal of the National Cancer Institute 65: 12651270.Google ScholarPubMed
Oshimi, K., Wakasugi, H., Seki, H., Kano, S. (1980b) Streptococcal preparation OK-432 augments cytotoxic activity against an erythroleukemic cell line in humans. Cancer Immunology Immunothreapy 9: 187192.Google Scholar
PMS report 1989 (no. 2): Pharmaceutical Affairs Bureau, Ministry of Health and Welfare Japan, 1134, December 20, 1989.Google Scholar
Saito, M., Ebina, T., Koi, M. (1982) Introduction of interferon in mice spleen cells by OK-432, a preparation of Streptococcus pyogenes. Cellular Immunology 68: 184192.CrossRefGoogle Scholar
Saito, M., Yamaguchi, T., Ebina, T., Koi, M., Aonuma, E., Usami, H., Ishida, N. (1983) In vitro production of immune interferon (IFNr) by murine spleen cells when different sensitizing antigens are used in vitro. Cellular Immunology 78: 379386.CrossRefGoogle Scholar
Saito, M., Nanjo, M., Aonuma, E., Noda, T., Nakadate, I., Ebina, T., Ishida, N. (1984) Activated macrophages are responsible for the tumour inhibitory effect in mice receiving intravenous injection of OK-432. International Journal of Cancer 33: 271276.CrossRefGoogle ScholarPubMed
Saito, M., Nanjo, M., Kataoka, M., Moriya, Y., Sugawara, Y., Yoshida, T., Ishida, N. (1988) Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumour site in mice. Cancer Research 48: 41634169.Google Scholar
Uchida, A., Mickshe, M. (1983a) Lysis of fresh human tumour cells by autologous peripheral blood lymphocytes and plural effusion lymphocytes activated by OK 432. Journal of the National Cancer Institute 71: 673680.Google Scholar
Uchida, A., Mickshe, M. (1983b) Lysis of fresh human tumour cells by autologous large granular lymphocytes from peripheral blood and plural effusions. International Journal of Cancer 32: 3741.CrossRefGoogle Scholar
Wakasugi, H., Kasahara, T., Minato, N., Hamuro, J., Miyata, M., Morioka, Y. (1982) In vitro potentiation of human natural killer cell activity by a streptococcal preparation, OK-Interferon and Interleukin-2 participation in the stimulation with OK-432. Journal of the National Cancer Institute 69: 807812.Google ScholarPubMed
Yamamoto, A., Nagamuta, M., Usami, H., Sugawara, Y., Watanabe, N., Niitsu, Y., Urushizaki, I. (1986) Release of tumour necrosis factor (TNF) into mouse peritoneal fluids by OK-432, a Streptococcal preparation. Immunopharmacology 11: 7986.CrossRefGoogle ScholarPubMed
Yamashita, R., Hirooka, T., Kamimoto, I., Miyauchi, Y. (1986) Prevention of growth of metastasis in rat liver by perioperative immunoactivation. Cancer Research 46: 31383141.Google Scholar
Yamaue, H., Tanimura, H., Tsunoda, T., Iwahashi, M., Tani, M., Tamai, M., Noguchi, K., Hotta, T., Arii, K. (1992) Enhancement of tumour cell susceptibility to lymphokineactivated killer cells by treatment with the Streptococcal preparation OK-432. Biotherapy 5: 8393.CrossRefGoogle Scholar
23
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *